Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

605

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Aclidinium Bromide 200 µg
DRUG: Aclidinium Bromide 400 µg

Sponsor

AstraZeneca